Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Hydrochloric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA known ✓ | P10253 | 1/20 | 0.33 |
| ▸ | PIK3CD known ✓ | O00329 | 2/20 | 0.32 |
| ▸ | ACE known ✓ | P12821 | 2/20 | 0.32 |
| ▸ | ATM | Q13315 | 1/20 | 0.57 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | MME | P08473 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL2147938 | 1.00 | ATM (0.57) | ATMTDP1GAAPIK3CDALDH1A1 | |
| Hydrochloric Acid SCHEMBL28731897 | 1.00 | ATM (0.57) | ATMTDP1GAAPIK3CDALDH1A1 | |
| Hydrochloric Acid SCHEMBL7143348 | 1.00 | ATM (0.57) | ATMTDP1GAAPIK3CDALDH1A1 | |
| SCHEMBL589712 | 0.98 | ATM (0.59) | ATMTDP1GAAPIK3CDALDH1A1 | |
| SCHEMBL1303907 | 0.98 | ATM (0.59) | ATMTDP1GAAPIK3CDALDH1A1 | |
| SCHEMBL690215 | 0.98 | ATM (0.59) | ATMTDP1GAAPIK3CDALDH1A1 | |
| SCHEMBL8989612 | 0.98 | ATM (0.59) | ATMTDP1GAAPIK3CDALDH1A1 | |
| SCHEMBL689912 | 0.98 | ATM (0.59) | ATMTDP1GAAPIK3CDALDH1A1 | |
| SCHEMBL7882438 | 0.98 | ATM (0.59) | ATMTDP1GAAPIK3CDALDH1A1 | |
| SCHEMBL19080644 | 0.98 | ATM (0.59) | ATMTDP1GAAPIK3CDALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 145 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-120130489-A | Application of hydroxyproline and derivatives thereof, biological herbicide, broad-spectrum herbicide and weed control method | 三亚市国家耐盐碱水稻技术创新中心 | 2025-06-13 | — | — | CN | disclosed |
| US-11779650-B2 | Pyrrolobenzodiazepine-antibody conjugates | MEDIMMUNE LIMITED (GB) | 2023-10-10 | — | — | US | disclosed |
| US-11771775-B2 | Pyrrolobenzodiazepine-antibody conjugates | MEDIMMUNE LIMITED (GB) | 2023-10-03 | — | — | US | disclosed |
| US-11690918-B2 | Pyrrolobenzodiazepine-anti-CD22 antibody conjugates | MEDIMMUNE LIMITED (GB) | 2023-07-04 | — | — | US | disclosed |
| US-20220298161-A1 | PYRROLOBENZODIAZEPINES AND CONJUGATES THEREOF | SPIROGEN SARL (CH) | 2022-09-22 | — | — | US | disclosed |
| EP-4039280-A1 | TARGETED PYRROLOBENZODIAZEPINE CONJUGATES | Seagen Inc. (US) | 2022-08-10 | — | — | EP | disclosed |
| CN-110256469-B | Pyrrolobenzodiazepines and conjugates thereof | 麦迪穆有限责任公司 | 2022-05-17 | — | — | CN | disclosed |
| EP-2558127-B1 | TARGETED PYRROLOBENZODIAZEPINE CONJUGATES | SEAGEN INC (US) | 2022-01-19 | — | — | EP | disclosed |
| US-20210137940-A1 | PYRROLOBENZODIAZEPINE-ANTI-PSMA ANTIBODY CONJUGATES | OWL ROCK OPPORTUNISTIC MASTER FUND I, L.P. | 2021-05-13 | — | — | US | disclosed |
| US-20200405880-A1 | PYRROLOBENZODIAZEPINE-ANTIBODY CONJUGATES | BLUE OWL OPPORTUNISTIC MASTER FUND I, L.P. (FORMERLY KNOWN AS OWL ROCK OPPORTUNISTIC MASTER FUND I, L.P.) | 2020-12-31 | — | — | US | disclosed |
| WO-2010043880-A1 | UNSYMMETRICAL PYRROLOBENZODIAZEPINE-DIMERS FOR TREATMENT OF PROLIFERATIVE DISEASES | SPIROGEN LIMITED (GB) | 2010-04-22 | — | — | WO | disclosed |
| WO-2010043877-A1 | PYRROLOBENZODIAZEPINES | SPIROGEN LIMITED (GB) | 2010-04-22 | — | — | WO | disclosed |
| US-7091363-B2 | Compounds for the preparation of carbapenem-type antibacterial agents | SANKYO COMPANY, LIMITED (JP) | 2006-08-15 | — | — | US | disclosed |
| US-7034150-B2 | Processes for the preparation of carbapenem-type antibacterial agents | SANKYO COMPANY, LIMITED (JP) | 2006-04-25 | — | — | US | disclosed |
| US-20060009508-A1 | Compounds for the preparation of carbapenem-type antibacterial agents | SANKYO COMPANY, LIMITED (JP) | 2006-01-12 | — | — | US | disclosed |
| EP-1338596-B1 | processes for the preparation of carbapenem-type antibacterial agents | SANKYO CO (JP) | 2006-01-11 | — | — | EP | disclosed |
| US-20030225055-A1 | Processes for the preparation of carbapenem-type antibacterial agents | SANKYO COMPANY, LIMITED (JP) | 2003-12-04 | — | — | US | disclosed |
| EP-1338596-A1 | PROCESS FOR PRODUCING CARBAPENEM-TYPE ANTIBACTERIAL | Sankyo Company, Limited (JP) | 2003-08-27 | — | — | EP | disclosed |
| US-5665371-A | SIDE EFFECT REDUCTION | HOERRMANN WILHELM (DE) | 1997-09-09 | — | — | US | disclosed |
| EP-0223850-B1 | MEDICINES WHICH CONTAIN DERIVATIVES OF PROLINE OR HYDROXYPROLINE | Hoerrmann, Wilhelm, Dr. (DE) | 1990-04-11 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11690918-B2 | Pyrrolobenzodiazepine-anti-CD22 antibody conjugates | CD22, CD2, CD2BP2 | GAA 1869/4885PIK3CD 4005/4885ACE 1587/4885 |
| US-11779650-B2 | Pyrrolobenzodiazepine-antibody conjugates | IL2RA, CD4, IL2 | GAA 4615/4885PIK3CD 3452/4885ACE 4820/4885 |
| US-20210137940-A1 | PYRROLOBENZODIAZEPINE-ANTI-PSMA ANTIBODY CONJUGATES | PSMA2, PSMA7, FOLH1 | GAA 716/4885PIK3CD 4102/4885ACE 2688/4885 |
| US-11771775-B2 | Pyrrolobenzodiazepine-antibody conjugates | CD79B, BCL6B, BCL6 | GAA 4115/4885PIK3CD 3635/4885ACE 4723/4885 |
| US-20030225055-A1 | Processes for the preparation of carbapenem-type antibacterial agents | OXA1L, MRPL21, IRAK1 | GAA 722/4885PIK3CD 404/4885ACE 1382/4885 |
| US-20060009508-A1 | Compounds for the preparation of carbapenem-type antibacterial agents | TET1, MRPL21, RPS6KA1 | GAA 863/4885PIK3CD 876/4885ACE 1290/4885 |
| US-20200405880-A1 | PYRROLOBENZODIAZEPINE-ANTIBODY CONJUGATES | IL2RA, CD4, IL2 | GAA 4615/4885PIK3CD 3452/4885ACE 4820/4885 |
| US-20220298161-A1 | PYRROLOBENZODIAZEPINES AND CONJUGATES THEREOF | HDAC10, PBDC1, PDCD10 | GAA 2546/4885PIK3CD 2779/4885ACE 4794/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.